Health Care & Life Sciences » Biotechnology | Emergent Biosolutions Inc.

Emergent Biosolutions Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
312,745.00
450,138.00
489,331.00
488,782.00
560,873.00
782,400
Cost of Goods Sold (COGS) incl. D&A
62,127.00
118,412.00
118,370.00
142,141.00
187,877.00
344,200
Gross Income
250,618.00
331,726.00
370,961.00
346,641.00
372,996.00
438,200
SG&A Expense
204,410.00
269,970.00
230,504.00
239,589.00
240,841.00
329,000
EBIT
46,208.00
61,756.00
-
107,052.00
132,155.00
109,200
Unusual Expense
3,406.00
3,700.00
1,057.00
1,530.00
7,870.00
19,400
Non Operating Income/Expense
426.00
2,926.00
153.00
263.00
815.00
1,600
Interest Expense
-
8,240.00
6,523.00
7,617.00
6,590.00
9,900
Pretax Income
43,367.00
53,062.00
135,716.00
99,221.00
118,633.00
81,500
Income Tax
13,108.00
16,321.00
44,300.00
36,697.00
36,039.00
18,800
Consolidated Net Income
30,259.00
36,741.00
91,416.00
62,524.00
82,594.00
62,700
Net Income
31,135.00
36,741.00
91,416.00
62,524.00
82,594.00
62,700
Net Income After Extraordinaries
31,135.00
36,741.00
119,962.00
73,272.00
82,594.00
62,700
Net Income Available to Common
31,135.00
36,741.00
62,870.00
51,776.00
82,594.00
62,700
EPS (Basic)
0.85
0.88
1.41
1.13
1.71
1.22
Basic Shares Outstanding
36,201.30
37,344.90
38,595.40
40,184.20
41,816.40
50,100
EPS (Diluted)
0.85
0.88
1.41
1.13
1.71
1.22
Diluted Shares Outstanding
36,747.60
45,802.80
47,255.80
49,335.10
50,327.90
51,400
EBITDA
65,166.00
94,209.00
175,792.00
145,281.00
172,969.00
170,500
Non-Operating Interest Income
139.00
320.00
572.00
1,053.00
1,753.00
-
Minority Interest Expense
876.00
-
-
-
-
-

About Emergent Biosolutions

View Profile
Address
400 Professional Drive
Gaithersburg Maryland 20879
United States
Employees -
Website http://www.emergentbiosolutions.com
Updated 07/08/2019
Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures that address public health and national security threats. It includes Chemical, Biological, Radiological, Nuclear and Explosive or CBRNE threats; as well as emerging infectious diseases. Its business units include Vaccines and Anti-Infectives; Antibody Therapeutics; Devices; and Contract Development and Manufacturing.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.